Roche Prepares for Windfall from Eli Lilly's Obesity Pill

Dow Jones07-23 21:16

1316 GMT - Roche Holding's first-half results got a boost from royalty and milestone payments related to Eli Lilly's Foundayo obesity pill, and the Swiss drugmaker expects that to increase in coming years, UBS analysts say in a research note. Roche's report features a strong increase in what the company calls "other revenue" partly driven by the Foundayo payments, the analysts say. "There was a notable contribution from the other revenue line and by 2030 Roche expects that 5% of group sales will come from other revenue," they add. The pill was discovered by Roche's majority-owned Chugai Pharmaceutical and licensed to Lilly. Roche shares rise 2%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 23, 2026 09:16 ET (13:16 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment